Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 4/2019

01-04-2019 | Research Article

Relapse patterns in patients with local and regional cutaneous melanoma

Authors: F. Tas, K. Erturk

Published in: Clinical and Translational Oncology | Issue 4/2019

Login to get access

Abstract

Background

The differences in features and risk factors for recurrence after definitive surgical excision are yet to be determined. The aim of this study was to understand these factors influencing recurrence patterns with local and regional disease in these patients.

Methods

A total of 365 relapsed patients, of whom 196 presented with local disease (stage I–II) and 169 with regional disease (stage III), were investigated in this retrospective study.

Results

The median time to initial recurrence for stage I–II and stage III patients was 22.3 and 13.4 months, respectively. Stage III patients were found to have higher Clark levels (p = 0.0001) and thicker lesions (p = 0.0001), and they were more significantly associated with the absence of tumor-infiltrating lymphocytes (p = 0.02) than stage I–II patients. Stage III patients were more significantly associated with recurrences compared to the stage I–II patients (p = 0.0001). Locoregional relapses were significantly associated with stage I–II melanomas, whereas majority of the distant metastases occurred in stage III patients (p = 0.01). Pulmonary metastasis was most frequently observed and the distribution of the sites for distant metastases was similar in both groups of the patients. On univariate analysis, male sex, increased tumor depth, presence of ulceration, nodular histopathology, higher Clark level, higher mitotic rate, and presence of lymphovascular invasions were found to predict shorter time to relapse for stage I–II patients; whereas only nodular pathology, presence of ulceration, and high mitotic rate were found to be associated with poor relapse-free survival in stage III patients. However, on multivariate analysis, only mitotic rate maintained its significance for both clinical staging groups.

Conclusion

Potential differences among early-stage melanoma patients, who developed recurrence, were noted and mitotic rate was found as the single significant prognostic factor for recurrence in both stage I–II and III patients.
Literature
1.
2.
Soong SJ, Harrison RA, McCarthy WH, Urist MM, Balch CM. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol. 1998;67:228–33.CrossRefPubMed
3.
Tas F. Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors. J Oncol 2012; Volume 2012, Article ID 647684.
4.
Tas F, Erturk K. Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival and influencing factors. Melanoma Res. 2017;27:134–9.CrossRefPubMed
5.
Meier F, Will S, Ellwanger U, Schlagenhauff B, Schittek B, Rassner G, Garbe C. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol. 2002;147:62–70.CrossRefPubMed
6.
Tejera-Vaquerizo A, Barrera-Vigo MV, Fernández-Canedo I, Blázquez-Sánchez N, Mendiola-Fernández M, Fernández-Orland A, et al. Longitudinal study of different metastatic patterns in the progression of cutaneous melanoma. Acta Dermosifiliogr. 2007;98:531–8.CrossRef
7.
Marcoval J, Ferreres JR, Martín C, Gómez S, Penín RM, Ochoa de Olza M, et al. Patterns of visceral metastasis in cutaneous melanoma: a descriptive study. Acta Dermosifiliogr. 2013;104:593–7.CrossRef
8.
Lee AY, Droppelmann N, Panageas KS, Zhou Q, Ariyan CE, Brady MS, et al. Patterns and timing of initial relapse in pathologic stage II melanoma patients. Ann Surg Oncol. 2017;24:939–46.CrossRefPubMed
9.
Romano E, Scordo M, Dusza SW, Ciot DG, Chapman PB. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol. 2010;28:3042–7.CrossRefPubMedPubMedCentral
10.
Thompson JF, Soong SJ, Balch CM, Gershenwald JE, Ding S, Coit DG, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol. 2011;29:2199–205.CrossRefPubMedPubMedCentral
11.
Donizy P, Kaczorowski M, Leskiewicz M, Zietek M, Pieniazek M, Kozyra C, et al. Mitotic rate is a more reliable unfavorable prognosticator than ulceration for early cutaneous melanoma: a 5-year survival analysis. Oncol Rep. 2014;32:2735–43.CrossRefPubMed
12.
Azzola MF, Shaw HM, Thompson JF, Soong SJ, Scolyer RA, Watson GF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer. 2003;97:1488–98.CrossRefPubMed
13.
Hale CS, Qian M, Ma MW, Scanlon P, Berman RS, Shapiro RL, et al. Mitotic rate in melanoma: prognostic value of immunostaining and computer-assisted image analysis. Am J Surg Pathol. 2013;37:882–9.CrossRefPubMedPubMedCentral
14.
Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:472–92.CrossRefPubMedPubMedCentral
15.
Keung EZ, Balch CM, Gershenwald JE, Halpern AC. Key changes in the AJCC eighth edition melanoma staging system. Melanoma Lett. 2017;36(1):1–9.
Metadata
Title
Relapse patterns in patients with local and regional cutaneous melanoma
Authors
F. Tas
K. Erturk
Publication date
01-04-2019
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 4/2019
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-018-1938-9

Other articles of this Issue 4/2019

Clinical and Translational Oncology 4/2019 Go to the issue

Research Article

Inhibiting 6-phosphogluconate dehydrogenase enhances chemotherapy efficacy in cervical cancer via AMPK-independent inhibition of RhoA and Rac1

Research Article

Goal-directed therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a prospective observational study

Brief Research Article

Impact of diabetes comorbidity on the efficacy and safety of FOLFOX first-line chemotherapy among patients with metastatic colorectal cancer: a pooled analysis of two phase-III studies

Research Article

Effect of Paclitaxel-based Hyperthermic Intraperitoneal Chemotherapy (HIPEC) on colonic anastomosis in a rat model

Brief Research Article

Optimization of oral chemotherapy in outpatient clinics in Spain: results from a survey of the Spanish Society of Medical Oncology (SEOM)

Research Article

Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits